||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

Helsinn Healthcare SA /
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual
Meeting for a RET inhibitor under co-development as an attractive compound for
anticancer therapy
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual
Meeting for a RET inhibitor under co-development as an attractive compound for
anticancer therapy

Lugano, Switzerland, and Tokyo, Japan, April 16, 2018 - Taiho Pharmaceutical
Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care
products, today announce that they are collaborating on the development of an
investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in
non-small cell lung cancer and other carcinomas.  Preliminary data regarding
TAS0286/HM05 is being presented at the American Association for Cancer Research
(AACR) meeting in Chicago, Illinois, U.S.A. Abstracts of the presentations are
available at: http://www.abstractsonline.com/pp8/#!/4562/presentation/6785

In in-vitro preclinical studies, TAS0286/HM05 inhibited the proliferation of
various RET fusions and RET-activating mutations positive cells as well as in
in-vivo preclinical studies, TAS0286/HM05 was shown to significantly inhibit the
growth of tumors harboring various RET fusions and activating mutations at a
range of 20 to 100 mg/kg/day without any body weight loss. The antitumor
efficacy of TAS0286/HM05 was more potent than pre-existing multikinase
inhibitors at their maximum tolerated dose. Primary data in mice studies has
shown an effect in tumor growth, providing an induced tumor regression of 40%
within 15 days. This study is being presented as a poster on Tuesday, April 17
from 1:00 PM to 5:00 PM CST in Poster Section 36, Poster Board Number 13
(Abstract No. 4784).

"Preliminary data for TAS0286/HM05 suggests it may be a potential agent for
future clinical development in patients with RET gene abnormalities," Sergio
Cantoreggi, Helsinn Group Chief Scientific Officer commented. "Helsinn and Taiho
Pharmaceutical have collaborated over many years on a number of programs and we
are delighted to be able to present this promising preclinical data, and we look
forward to further collaboration."

"Over the years, Taiho Pharmaceutical has collaborated with Helsinn as an
excellent partner in the development and marketing of new drugs. I am excited
about the new collaboration with Helsinn on the selective RET inhibitor that was
discovered by the Taiho Tsukuba Research Center. I look forward to the success
of the program and the strengthening of our partnership." Teruhiro Utsugi, Taiho
Managing Director commented.

TAS0286/HM05 was discovered by Taiho Pharmaceutical and it will now be jointly
developed by Helsinn and Taiho Pharmaceutical. TAS0286/HM05 is an
investigational agent and is not approved for commercial use in any country.


About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of
marketed cancer care products and a robust drug development pipeline. Since
1976, Helsinn has been improving the everyday lives of patients, guided by core
family values of respect, integrity and quality. The Group works across
pharmaceuticals, biotechnology, medical devices and nutritional supplements and
has expertise in research, development, manufacture and the commercialization of
therapeutic and supportive care products for cancer, pain and inflammation and
gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund
to support early-stage investment opportunities in areas of unmet patient need.
The company is headquartered in Lugano, Switzerland, with operating subsidiaries
in Switzerland, Ireland, the U.S., Monaco and China, as well as a product
presence in approximately 190 countries globally.


For more information, please visit www.helsinn.com


About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd.
(https://www.otsuka.com/en/), is an R&D-driven specialty pharma focusing on the
three fields of oncology, allergy and immunology, and urology. Its corporate
philosophy takes the form of a pledge: "We strive to improve human health and
contribute to a society enriched by smiles." In the field of oncology in
particular, Taiho Pharmaceutical is known as a leading company in Japan for
developing innovative medicines for the treatment of cancer, a reputation that
is rapidly expanding through their extensive global R&D efforts. In areas other
than oncology as well, the company creates and markets quality products that
effectively treat medical conditions and can help improve people's quality of
life. Always putting customers first, Taiho Pharmaceutical also aims to offer
consumer healthcare products that support people's efforts to lead fulfilling
and rewarding lives.

For more information about Taiho Pharmaceutical, please visit
https://www.taiho.co.jp/en/.

For more information please contact:

Helsinn Group
Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter,
LinkedIn and Vimeo.


Taiho Pharmaceutical Co., Ltd.
Emiko Nonami
Public Relations
Tokyo, Japan
Tel: +81-3-3293-2878
th-koho@taiho.co.jp



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Helsinn Healthcare SA via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.092 Sekunden